AMLM12 | The Australasian Leukaemia and Lymphoma Group

A randomised trial of idarubicin dose escalation in consolidation therapy following intensive induction chemotherapy incorporating high dose cytarabine in patients with untreated adult acute myeloid leukaemia, to evaluate safety and improve remission rate.

DOI number	10.58109/gfyk-k522
Publisher	Australasian Leukaemia and Lymphoma Group (ALLG)
Creator(s)	Australasian Leukaemia and Lymphoma Group (ALLG) Kenneth Bradstock (Westmead Hospital)
Date Made Available	2023
Dataset	Individual participant data (IPD) in aggregate form
Description of Dataset	Dataset includes: Data for 442 patients Includes first Australian study conduceted in AML using dose escalation therapy Also investigates use of antiemetics and oral mucositis medication Dataset includes demographic data, diagnostic, treatment data, outcome data induction and consolidation treatment, including measurements for progression and clinical outcomes Patients who underwent BMT were censored for this study
Funding	Australasian Leukaemia and Lymphoma Group (ALLG)
Subject (ANZSRC Category)	Chemotherapy
ANZCTR Reference	ACTRN12605000095662
Publication(s)	A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia Utility of a clinical risk score to identify high-risk patients with de novo acute myeloid leukaemia in first remission after high-dose cytarabine (HiDAC) based induction chemotherapy Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies
Dataset Access	Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au